Anna Geng

Anna Geng, on behalf of Matt O'Brien from Piper Sandler, asked about the remaining potential for cost reductions and synergy optimization within the Nevro business, questioning if more synergies could be realized beyond initial expectations, similar to the NuVasive acquisition.

Answer

Kyle Kline, Chief Financial Officer, stated that most synergy actions for Nevro, primarily in G&A (headcount and non-headcount costs), have largely taken place over the first nine months. Moving forward, the focus is on maintaining the sales force and growing sales volume to achieve incremental leverage and profitability. While manufacturing aspects (COGS) are being evaluated for minor tweaks, no large-scale synergies are expected for Nevro beyond what has already been executed.

Anna Geng inquired about remaining opportunities for cost reductions and synergy optimization within the Nevro business, and whether more synergies than originally anticipated, similar to NuVasive, are possible.

Answer

Kyle Kline, Chief Financial Officer, stated that Nevro's synergy focus has primarily been on G&A (headcount and non-headcount costs) over the first nine months, with those actions largely complete. Future focus is on sales volume growth for incremental leverage, with manufacturing (COGS) as a potential area for minor improvements, but no large-scale synergies are expected.